My Hematocrit Hit 59% on TRT: Tony Huge’s Video Guide
Tony Huge’s hematocrit came back at 59%. That number is the headline, but the video is really about the trade nobody explains when they tell a man on testosterone to go donate blood. The draw fixes thickness this month and quietly drains iron all year, and Tony argues you cannot manage one without watching the other.
Does TRT Cause Hair Loss? Gel vs Injections vs Enclomiphene: Tony Huge’s Video Guide
Tony Huge has run testosterone for 14 years and still has his hair, and this video is his attempt to explain why that might not be luck. His answer to the TRT hair loss question is that male pattern baldness is a DHT problem rather than a testosterone problem, which means the route you use to raise testosterone matters more than the number you land on. He compares gel, injections, and enclomiphene on one metric, how much DHT each one generates per unit of testosterone, and then tells you exactly where the hormone data ends and the guesswork begins.
Smellmaxxing and 2-Nonenal: The Science of Old People Smell: Tony Huge’s Video Guide
Tony Huge has spent years reversing his biological age, and then a girlfriend told him he smelled old. This video is what he found: a molecule called 2-nonenal that shows up on skin after about 40, a discovery paper written by the company that had already patented the fix, an independent study that flips the story, and a grade for every claimed remedy. He calls it smellmaxxing, and most of the industry advice fails his ladder.
Can Enclomiphene Get Testosterone Over 1,000? Tony Huge’s Video Guide
More than 1,100 men have been through enclomiphene trials, and exactly one of those trials ever counted how many blood samples crossed 1,000 ng/dL. What it printed is not what anyone online is quoting. Tony Huge goes through every published record of enclomiphene testosterone levels, the registry postings, and the sponsor’s own tables, and ends up with a different question: why did a company that drew blood every hour for 24 hours stop counting at 500?
BPC-157 Explained: Rat Studies, Human Data and Trade-Offs: Tony Huge’s Video Guide
BPC-157 has zero completed human trials, and Tony Huge uses it anyway. When he eats wheat his gut normally takes five days or more to recover; on BPC-157 it takes one or two, every time, across roughly 60 repetitions. This video is about holding both facts at once: the rat literature that built the peptide’s reputation, the very short list of human evidence, the regulatory gray zone, and how to read your own results without fooling yourself.
Does RAD 140 Build Muscle? What the Research Says: Tony Huge’s Video Guide
The biggest myth about RAD 140 is that it has never been tested in a human. It has, but the trial was in 22 women with advanced breast cancer, and it measured receptor activity and liver markers, not how much muscle a trained man can add. Tony Huge walks through that study, the 2025 rat data, the mouse frailty findings, and the LGD-4033 suppression trial to show what the research does and does not answer.
Tesamorelin Exposed: Same Growth Hormone, Different Doorway: Tony Huge’s Video Guide
Tesamorelin does one thing: it raises your own growth hormone. Everything it does to visceral fat, it does through that hormone, and the FDA label says so. Tony Huge’s argument in this video is that if growth hormone is the whole mechanism, then the molecule that released it is interchangeable, and the tesamorelin vs ipamorelin comparison is his worked example: a peptide costing a tenth as much that also releases growth hormone in pulses deserves the same credit. He walks the label, the fat-cell biology, the pivotal trial, the strongest counterargument, and the money, and then says plainly where sound reasoning stops being a trial.
Methylene Blue Explained: What the Studies Show: Tony Huge’s Video Guide
Methylene blue was a fabric dye in 1876 before it became an approved emergency medicine, and Tony Huge says he and Coach Trevor were experimenting with it as a biohacking tool a decade before anyone on YouTube mentioned it. This video is his walk through the methylene blue studies: a plain-language version of the mechanism, every dose range the trials actually used, a grade for each claim from A to E, and the one risk that has kept his own dosing low for ten years.
Cardio Doesn’t Lower Cholesterol the Way You Think: Tony Huge’s Video Guide
Cardio lowers LDL by about half a point. That is the average across 31 trials and 1,800 people, and it is the number Tony Huge builds this whole video around. Exercise is a triglyceride drug, it nudges HDL, and it barely touches the particle count that actually drives heart disease. Tony goes through the trial data, the timing trap in your blood draw, walking versus jogging, and the so-called exercise mimetics, then explains why he still thinks exercise protects the heart anyway.
My Heart Genetics Are Terrible, So I Tested Everything: Tony Huge’s Video Guide
Tony Huge calls himself a walking cardiovascular time bomb: one copy of APOE4, homozygous risk at all three standard 9p21 markers, none of the protective variants, and 14 years of testosterone and anabolics on top. Then he pulls the blood work. LDL 82.6. Lipoprotein(a) at the floor of the range. This video is his audit of both columns, what the genetics predicted, what the labs actually show, and the 30-year-old testosterone study he thinks got buried.